other material
confidence high
sentiment positive
materiality 0.80
RMC-6236 shows 38% ORR in NSCLC, 27-36% in PDAC; median PFS 9.8 mo and 8.5-8.8 mo
Revolution Medicines, Inc.
- NSCLC efficacy: ORR 38% (15/40), median PFS 9.8 mo, median OS 17.7 mo in RAS G12X pts (cutoff Sept 30, 2024).
- PDAC 2L: ORR 36% (G12X) and 27% (broader RAS); median PFS 8.8 and 8.5 mo; 6-mo OS 100% and 97% (cutoff Jul 23, 2024).
- PDAC safety at 300 mg: 34% Grade ≥3 TRAEs, no Grade 5; median duration 5.2 mo, mean dose intensity 89%.
- NSCLC safety: Grade ≥3 TRAEs 27% overall, 41% at 300 mg; one Grade 4 pneumonitis at 300 mg; median duration 5.5 mo (120-220 mg).
- Combination RMC-6236+RMC-6291 in KRAS G12Ci-experienced CRC: ORR 25% (3/12), DCR 92%; plans for Phase 3 NSCLC trial vs docetaxel.